Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen. Comera Life Sciences' proprietary SQore™ platform is designed to transform intravenous (“IV”) biologics into subcutaneous (“SQ”) versions that patients can self-administer in a single dose. As a gentler, more convenient form of medicine, SQore-based therapeutics may improve the patient experience, increase patient adherence and reduce costly institutional burdens.